



Press Release

Wednesday, July 23, 2014

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Strides Arcolab receives USFDA approval for Tacrolimus Capsules

Product to be launched immediately

July 23, 2014: Strides Arcolab (BSE: 532531, NSE: STAR) today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg**

According to IMS data as on September 2013, the US market for generic Tacrolimus is approximately USD 676 Million.

The product will be manufactured at the Company's Oral dosage facility at Bangalore and marketed directly by Strides in the US Market.


About Tacrolimus capsules

Tacrolimus capsule is an immunosuppressant used for preventing organ rejection in certain patients following liver, kidney, or heart transplant. It may be used along with other medicines. It blocks the action of certain blood cells (eg, T lymphocytes) that can cause the body to reject the transplanted organ.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.



Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mohan Kumar, CEO – Pharma +91 80 6784 0748	Weber Shandwick
Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745	Kaveri Mandanna: +91 90089 59697 KMandanna@webershandwick.com
	Mahesh Nair: +91 98803 76648 MNair@webershandwick.com

